Understand the source comparison
Sermorelin + GHRP vs. Sermorelin + CJC-1295: Comparison
Sermorelin + GHRP-2 Dual-pathway (GHRH + ghrelin receptor) Pulsatile, amplified peaks High. 30–50% increase vs. single compound 200mcg sermorelin + 100–200mcg GHRP-2 Research protocols focused on maximising pulsatile GH release Gold standard for synergistic GH
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Sermorelin + GHRP-2
- Dual-pathway (GHRH + ghrelin receptor)
- Pulsatile, amplified peaks
- High. 30–50% increase vs. single compound
- 200mcg sermorelin + 100–200mcg GHRP-2
- Research protocols focused on maximising pulsatile GH release
- Gold standard for synergistic GH amplification. Exploits two independent receptor pathways
- Sermorelin + Ipamorelin
- Dual-pathway (GHRH + selective ghrelin agonist)
- Pulsatile, minimal cortisol/prolactin elevation
- High. Similar to GHRP-2 but cleaner profile
- 200mcg sermorelin + 200–300mcg ipamorelin
- Protocols where cortisol/prolactin elevation is undesirable
- Preferred for long-term research due to selective receptor profile
- Sermorelin + CJC-1295 (no DAC)
- Both activate GHRH receptor
- Pulsatile, extended duration
- Low. Minimal synergy (same receptor)
- 200mcg sermorelin + 100mcg CJC-1295
- Extending GH pulse duration without GHRP side effects
- Redundant. Choose one GHRH analogue, pair with a GHRP instead
- Sermorelin + MK-677
- GHRH receptor + oral ghrelin mimetic
- Pulsatile (sermorelin) + sustained baseline (MK-677)
- Moderate. Baseline IGF-1 elevation with preserved pulses
- 200mcg sermorelin + 12.5–25mg MK-677 daily
- Protocols requiring sustained IGF-1 with pulsatile GH
- Risk of receptor desensitisation after 8–12 weeks of continuous MK-677